ANNUAL FINANCIAL REPORT FOR THE YEAR ENDED 31 MARCH 2024
18 JUNE 2024
NORTHERN VENTURE TRUST PLC
ANNUAL FINANCIAL REPORT FOR THE YEAR
ENDED 31 MARCH 2024
Northern Venture Trust PLC is a Venture Capital
Trust (VCT) advised by Mercia Fund Management Limited. The trust
was one of the first VCTs launched on the London Stock Exchange in
1995. It invests mainly in unquoted venture capital holdings and
aims to provide high long-term tax-free returns to shareholders
through a combination of dividend yield and capital growth.
Financial highlights
(comparative figures as at 31 March 2023):
|
|
12m period ended |
Unaudited 12m period ended |
18m period ended |
|
|
31 March |
31 March |
31 March |
|
|
2024 |
2023 |
2023 |
|
|
|
|
|
Net assets |
|
£114.8m |
£102.5m |
£102.5m |
|
|
|
|
|
Net asset value per share |
|
60.3p |
62.1p |
62.1p |
|
|
|
|
|
Return per share |
|
|
|
|
Revenue |
|
0.6p |
(0.3)p |
(0.3)p |
Capital |
|
1.2p |
(2.1)p |
(5.7)p |
Total |
|
1.8p |
(2.4)p |
(6.0)p |
|
|
|
|
|
Dividend per share declared in respect of the
period |
|
|
|
|
Interim dividend |
|
1.6p |
– |
2.0p |
Second interim dividend |
|
– |
2.0p |
2.0p |
Proposed final dividend |
|
1.6p |
2.0p |
2.0p |
Total |
|
3.2p |
4.0p |
6.0p |
|
|
|
|
|
Return to
shareholders since
launch |
|
|
|
|
Net asset value
per share |
|
60.3p |
62.1p |
62.1p |
Cumulative
dividends paid per share* |
|
192.1p |
188.5p |
188.5p |
Cumulative return per share |
|
252.4p |
250.6p |
250.6p |
|
|
|
|
|
Mid-market share price at end of period |
|
57.5p |
57.5p |
57.5p |
|
|
|
|
|
Share price discount to net asset value |
|
4.6% |
7.4% |
7.4% |
|
|
|
|
|
Annualised tax-free dividend yield** |
|
5.2% |
5.8% |
5.4% |
*Excluding proposed final dividend payable on 23 August 2024
** Based on net asset value per share at the start of the
period
Enquiries:
James Sly / Sarah Williams, Mercia Asset Management PLC – 0330 223
1430
Website: www.mercia.co.uk/vcts/nvt/
Chair’s statement
Over the past twelve months, the UK economy has faced
challenging macroeconomic conditions, with inflationary pressures,
higher interest rates, and a technical recession. Alongside this,
uncertainties posed by geopolitical events and conflicts have
created volatility in financial markets. Whilst some of these
headwinds have shown signs of abating recently, the impact of this
backdrop during the year created challenges and opportunities for
the portfolio.
It is pleasing to note that the valuation of our unquoted
portfolio has increased during the past year. Investment activity
remained consistent with the previous two years, with £15.0 million
invested in 6 new and 14 existing portfolio companies.
Despite difficult fundraising conditions, our share offer of £20
million was oversubscribed and I would like to thank existing
shareholders for their continued support and warmly welcome new
investors. Proceeds from the share offer together with sales
proceeds from investments mean that the Company is well positioned
both to pursue new opportunities to support small and medium
businesses and to work with existing portfolio companies to realise
their growth plans.
Results and dividend
In the year ended 31 March 2024 the Company delivered a return on
ordinary activities of 1.8 pence per share (18-months ended 31
March 2023: minus 6.0 pence), representing a total return of 2.9%
on the opening net asset value (NAV) per share. The NAV per share
as at 31 March 2024, after deducting dividends paid during the year
of 3.6 pence, was 60.3 pence, compared with 62.1 pence at 31 March
2023.
It was a quieter year for realisation activity, with the lower
number of transactions reflecting the underlying tone of the
market. The most notable realisation was Evotix, sold for initial
net proceeds of £12.7 million compared to an original cost of £2.8
million, a 4.6 times initial return. As Evotix continued to meet
its forecasts following its sale, contractual deferred proceeds of
£0.8 million were also received after the balance sheet date and
have been included in these results.
Investment income was higher than the prior period at £2.2
million (18-months ended 2023: £0.9 million), due largely to the
increased interest rate environment resulting in a higher yield on
the Company’s liquid cash deposits. During the year we made the
decision to liquidate the Company’s portfolio of listed shares with
RBC Brewin Dolphin, placing the cash in a money market fund
attracting a higher yield.
In 2018 we revised our dividend policy in the light of the new
VCT rules for investment introduced in 2015 and 2017, which we
expected to result in more volatile returns. We introduced an
annualised target dividend yield of 5% of opening NAV, which has
been exceeded in every period since. Having already declared an
interim dividend of 1.6 pence per share which was paid in January
2024, your Directors now propose a final dividend of 1.6 pence per
share. The total of 3.2 pence per share is equivalent to 5.2% of
the opening net asset value per share of 62.1 pence. The final
dividend, if approved, will be paid on 23 August 2024 to
shareholders on the register on 26 July 2024.
Our dividend investment scheme, under which dividends can be
reinvested in new ordinary shares free of dealing costs and with
the benefit of the tax reliefs available on new VCT share
subscriptions, continues to operate with around 17% participation
during the year. Instructions on how to join the scheme are
included within the dividend section of our website, which can be
found here: mercia.co.uk/vcts/nvt/.
Investment portfolio
The Company continues to be a generalist investor, with large
allocations in the software, healthcare / life science and consumer
sectors. Given the prevailing market sentiment towards consumer
investments and a weaker market for software businesses over the
past year, investment has been predominantly directed into a number
of new healthcare / life science businesses, whilst we remained
open to other opportunities as they arose.
Investment activity has remained strong, with £6.9 million of
capital provided to six new venture capital investments and £8.1
million of follow-on capital invested into the existing portfolio.
We also made progress in realising the Company’s mature portfolio
acquired under the previous VCT rules with the remaining such
investments now valued at £16.0 million (31 March 2023: £17.3
million).
The value of the portfolio increased by £2.5 million (1.4 pence
per share) in the year, with several portfolio companies enjoying
significant growth – Pure Pet Food, Project Glow Topco (t / a
Currentbody.com), Pimberly and Gentronix all increased in value by
over £1 million. Against this there were some significant write-
downs in the investments in Volumatic Holdings and Grip UK (t / a
The Climbing Hangar). Additionally the value of musicMagpie, which
is listed on AIM, fell by £0.8 million.
Share offers and liquidity
In April 2023 gross proceeds of £6.0 million were received from the
fully subscribed 2022/23 share offer as 9,741,182 new ordinary
shares were issued. The Board was also pleased to announce recently
the successful subscription of the 2023/24 share offer, which
amounted to £20 million. In relation to this offer, an interim
allotment of 19,211,579 new ordinary shares was issued in December
2023, generating £12.2 million in gross subscriptions, and
12,234,307 new ordinary shares were issued in April 2024, yielding
gross subscriptions of £7.8 million.
The Board continues to monitor liquidity carefully and will
publish details of the plans to raise funds in the 2024/25 tax year
in due course.
Share buy-backs
We have maintained our policy of being willing to buy back the
Company’s shares in the market when necessary, in order to maintain
liquidity, at a 5% discount to NAV. During the year ended 31 March
2024 a total of 5,263,205 (18-months ended 31 March 2023:
7,335,532) shares were repurchased by the Company for cancellation
at an average price of 58.0 pence (18-months ended 31 March 2023:
61.2 pence), representing 3.2% (18-months ended 31 March 2023:
4.6%) of the opening issued share capital.
Responsible investment
The Company is mindful of its Environmental, Social and Governance
(ESG) responsibilities and we have outlined our evolving approach
in the annual report.
VCT legislation and qualifying status
The Company has continued to meet the stringent and complex
qualifying conditions laid down by HM Revenue & Customs for
maintaining its approval as a VCT. The Investment Adviser monitors
the position closely and reports regularly to the Board. Philip
Hare & Associates LLP has continued to act as independent
adviser to the Company on VCT taxation matters.
The Board was pleased to note the recognition by the UK
Government of the vital role that VCTs perform, following the
announcement of the extension to VCT tax relief for a further 10
years to 2035. The Board considers that the Company, and VCTs more
generally, are successfully delivering in line with the
Government’s mandate, which is to invest and support higher- risk,
early-stage businesses.
Whilst no further amendments to VCT legislation have been
announced, it is possible that further changes will be made in the
future. We will continue to work closely with our Investment
Adviser to maintain compliance with the scheme rules at all
times.
Annual General Meeting
The Company’s AGM will be held at 11.30am on 30 July 2024. The AGM
provides an excellent opportunity for shareholders, the Directors
and the Investment Adviser to meet in person, exchange views and
comment. We will hold the AGM in person at Howard Kennedy LLP, No.
1 London Bridge, London SE1 9BG. Following positive feedback
received from the last four years, we also intend to offer remote
access for shareholders through an online webinar facility for
those who would prefer not to travel. Full details and formal
notice of the AGM are set out in a separate document. Please note
that shareholders attending remotely must register their votes
ahead of time, as it will not be possible to count votes from
online participants at the AGM.
Board succession
We announced the appointment of Brigid Sutcliffe to the Board in
April as Chair-elect of the Audit Committee in advance of Richard
Green’s retirement from the Board at the AGM. Brigid brings a
wealth of experience in listed investment trusts, particularly in
the areas of finance, audit and risk management governance. The
Board continues to execute its succession plans, and expects to
make one further appointment later this year.
Further biographical details for all the Directors can be found
in the annual report.
On behalf of the Board and all shareholders, I would like to
thank Richard for his very significant contribution to the Company.
He has served as a Director for the past 10 years, most recently as
Chair of the Audit Committee but his contribution goes way beyond
that. His experience in managing and chairing private equity funds
has been invaluable as we navigated the new rules on investing and
the transfer of the Company’s management contract to Mercia.
I will be retiring at this AGM, my tenth as Chair and so will
not be standing for re-election. It has been a privilege to serve
you as Chair during such an eventful decade. The EU’s decision in
2015 that VCTs were not taking enough risk led to a significant
re-focus and hiring of new resources within NVM, our Investment
Adviser at the time. NVM’s decision to sell our management contract
to Mercia in 2019 led to numerous discussions and meetings as a
board to ensure the Company’s interests and opportunities were
protected and indeed enhanced under the new ownership. Almost as
soon as these arrangements were completed the pandemic struck in
2020, leading to months of uncertainty for many of our investee
companies, which needed sustained support both from Mercia
operationally and from ourselves as shareholders.
I would like to thank all my colleagues on the Board over the
years for their considerable support, which has made my job as
Chair possible. I leave the Board in good shape under the
leadership of Deborah Hudson, who I am sure will be an excellent
Chair. Finally thank you, our shareholders, for your support over
the years. As a Board we are always cognisant that we represent you
as the owners of this Company and have your best interests at the
centre of our discussions and decisions.
Outlook
We are encouraged by the recent reductions in inflation and
expectations of lower interest rates, which create a more
favourable environment in the UK to provide capital and support to
innovative early-stage businesses. The Directors remain optimistic
about the resilience, diversity and growth potential of the
portfolio and its ability to generate long-term shareholder
value.
Simon Constantine
Chair
18 June 2024
Extracts from the audited financial statements for the year ended
31 March 2024 are set out below.
Income
Statement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year ended
31 March 2024 |
|
18-month period ended
31 March 2023 |
|
|
|
|
|
|
|
|
|
|
|
Revenue |
Capital |
Total |
|
Revenue |
Capital |
Total |
|
|
£000 |
£000 |
£000 |
|
£000 |
£000 |
£000 |
|
|
|
|
|
|
|
|
|
Gain / (loss) on
disposal of investments |
|
- |
1,203 |
1,203 |
|
- |
2,944 |
2,944 |
Unrealised fair value gains / (losses) on investments |
|
- |
2,499 |
2,499 |
|
- |
(9,776) |
(9,776) |
|
|
- |
3,702 |
3,702 |
|
- |
(6,832) |
(6,832) |
|
|
|
|
|
|
|
|
|
Dividend and
interest income |
|
2,220 |
- |
2,220 |
|
948 |
- |
948 |
Investment
management fee |
|
(516) |
(1,549) |
(2,065) |
|
(811) |
(2,432) |
(3,243) |
Other expenses |
|
(641) |
- |
(641) |
|
(796) |
- |
(796) |
|
|
|
|
|
|
|
|
|
Return
before tax |
|
1,063 |
2,153 |
3,216 |
|
(659) |
(9,264) |
(9,923) |
Tax on return |
|
79 |
(79) |
- |
|
181 |
(181) |
- |
|
|
|
|
|
|
|
|
|
Return after tax |
|
1,142 |
2,074 |
3,216 |
|
(478) |
(9,445) |
(9,923) |
|
|
|
|
|
|
|
|
|
Return per share |
|
0.6p |
1.2p |
1.8p |
|
(0.3)p |
(5.7)p |
(6.0)p |
Balance Sheet |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31 March 2024 |
|
31 March 2023 |
|
|
£000 |
|
£000 |
|
|
|
|
|
Fixed
assets |
|
|
|
|
Investments |
|
82,574 |
|
88,609 |
|
|
|
|
|
Current assets |
|
|
|
|
Debtors |
|
951 |
|
70 |
Cash and cash equivalents |
|
31,497 |
|
14,001 |
|
|
32,448 |
|
14,071 |
|
|
|
|
|
Creditors (amounts falling due within one
year) |
|
(191) |
|
(183) |
|
|
|
|
|
Net current assets |
|
32,257 |
|
13,888 |
|
|
|
|
|
Net assets |
|
114,831 |
|
102,497 |
|
|
|
|
|
Capital and reserves |
|
|
|
|
Called-up
equity share capital |
|
47,615 |
|
41,230 |
Share
premium |
|
30,418 |
|
19,394 |
Capital
redemption reserve |
|
6,658 |
|
5,342 |
Capital
reserve |
|
28,099 |
|
34,433 |
Revaluation
reserve |
|
882 |
|
1,698 |
Revenue reserve |
|
1,159 |
|
400 |
|
|
|
|
|
Total equity shareholders' funds |
|
114,831 |
|
102,497 |
|
|
|
|
|
Net asset value per share |
|
60.3p |
|
62.1p |
Statement of changes in equity |
for the year ended 31 March 2024 |
|
|
Non-distributable reserves |
Distributable reserves |
Total |
|
|
Called-up share capital |
Share premium |
Capital redemption reserve |
Revaluation reserve |
Capital
reserve |
Revenue reserve |
|
|
|
£000 |
£000 |
£000 |
£000 |
£000 |
£000 |
£000 |
At 31 March 2023 |
|
41,230 |
19,394 |
5,342 |
1,698 |
34,433 |
400 |
102,497 |
|
|
|
|
|
|
|
|
|
Return after
tax |
|
- |
- |
- |
(816) |
2,890 |
1,142 |
3,216 |
Dividends
paid |
|
- |
- |
- |
- |
(6,156) |
(383) |
(6,539) |
Net proceeds
of share issues |
|
7,701 |
11,024 |
- |
- |
- |
- |
18,725 |
Shares
purchased for cancellation |
|
(1,316) |
- |
1,316 |
- |
(3,068) |
- |
(3,068) |
|
|
|
|
|
|
|
|
|
At 31 March 2024 |
|
47,615 |
30,418 |
6,658 |
882 |
28,099 |
1,159 |
114,831 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For
the 18-month period ended
31 March 2023 |
|
Non-distributable reserves |
Distributable reserves |
Total |
|
|
Called-up share capital |
Share premium |
Capital redemption reserve |
Revaluation reserve |
Capital
reserve |
Revenue reserve |
|
|
|
£000 |
£000 |
£000 |
£000 |
£000 |
£000 |
£000 |
At 30 September 2021 |
|
40,268 |
14,608 |
3,508 |
21,430 |
38,325 |
1,159 |
119,298 |
|
|
|
|
|
|
|
|
|
Return after
tax |
|
- |
- |
- |
(19,732) |
10,287 |
(478) |
(9,923) |
Dividends
paid |
|
- |
- |
- |
- |
(9,609) |
(281) |
(9,890) |
Net proceeds
of share issues |
|
2,796 |
4,786 |
- |
- |
- |
- |
7,582 |
Shares
purchased for cancellation |
|
(1,834) |
- |
1,834 |
- |
(4,570) |
- |
(4,570) |
|
|
|
|
|
|
|
|
|
At 31 March 2023 |
|
41,230 |
19,394 |
5,342 |
1,698 |
34,433 |
400 |
102,497 |
Statement of cash flows |
|
|
|
|
|
for
the year ended 31 March 2024 |
|
|
Year ended |
|
18 month period ended |
|
|
|
31 March 2024 |
|
31 March 2023 |
|
|
|
£000 |
|
£000 |
Cash
flows from operating activities |
|
|
|
|
|
Return before
tax |
|
|
3,216 |
|
(9,923) |
Adjustments
for: |
|
|
|
|
|
(Gain) / loss on
disposal of investments |
|
|
(1,203) |
|
(2,944) |
Movements in fair
value of investments |
|
|
(2,499) |
|
9,776 |
(Increase) /
decrease in debtors |
|
|
(103) |
|
238 |
Increase /
(decrease) in creditors |
|
|
8 |
|
(2,496) |
|
|
|
|
|
|
Net cash inflow
/ (outflow) from
operating activities |
|
|
(581) |
|
(5,349) |
|
|
|
|
|
|
Cash
flows from investing activities |
|
|
|
|
|
Purchase of
investments |
|
|
(15,351) |
|
(27,450) |
Proceeds on
disposal of investments |
|
|
24,310 |
|
28,572 |
|
|
|
|
|
|
Net cash inflow / (outflow) from investing
activities |
|
|
8,959 |
|
1,122 |
|
|
|
|
|
|
|
|
|
|
|
|
Cash
flows from financing activities |
|
|
|
|
|
Issue of
ordinary shares |
|
|
19,353 |
|
7,796 |
Share issue
expenses |
|
|
(628) |
|
(214) |
Purchase of
ordinary shares for cancellation |
|
|
(3,068) |
|
(4,570) |
Equity
dividends paid |
|
|
(6,539) |
|
(9,890) |
|
|
|
|
|
|
Net cash inflow
/ (outflow) from
financing activities |
|
|
9,118 |
|
(6,878) |
|
|
|
|
|
|
|
|
|
|
|
|
Increase / (decrease) in cash and cash
equivalents |
|
|
17,496 |
|
(11,105) |
Cash and cash equivalents at beginning of period |
|
|
14,001 |
|
25,106 |
Cash and cash equivalents at end of year |
|
|
31,497 |
|
14,001 |
INVESTMENT PORTFOLIO SUMMARY
as at 31 March 2024
|
|
Cost |
Valuation |
Like for like valuation increase / (decrease) over period |
% of net assets by value |
|
|
£'000 |
£'000 |
£'000 |
% |
Fifteen largest venture capital investments |
|
|
|
|
1 |
Gentronix |
1,362 |
4,323 |
1,241 |
3.8% |
2 |
Project Glow
Topco (t/a Currentbody.com) |
1,686 |
3,557 |
1,871 |
3.1% |
3 |
Pimberly |
2,060 |
3,480 |
1,420 |
3.0% |
4 |
Tutora (t/a
Tutorful) |
3,305 |
3,305 |
(114) |
2.9% |
5 |
Newcells
Biotech |
3,011 |
3,257 |
206 |
2.8% |
6 |
Pure Pet
Food |
1,774 |
3,210 |
1,366 |
2.8% |
7 |
Rockar |
1,877 |
3,166 |
371 |
2.8% |
8 |
Adludio |
2,629 |
2,639 |
10 |
2.3% |
9 |
Netacea |
2,631 |
2,631 |
-- |
2.3% |
10 |
Grip-UK (t/a
Climbing Hangar) |
3,885 |
2,607 |
(1,278) |
2.3% |
11 |
Buoyant
Upholstery |
1,173 |
2,569 |
674 |
2.2% |
12 |
Biological
Preparations Group |
2,366 |
2,176 |
(92) |
1.9% |
13 |
Ridge
Pharma |
1,497 |
2,168 |
668 |
1.9% |
14 |
Broker
Insights |
2,076 |
2,084 |
9 |
1.8% |
15 |
Forensic
Analytics |
2,016 |
2,016 |
-- |
1.8% |
Other venture capital investments |
|
|
-- |
|
16 |
Clarilis |
1,972 |
1,972 |
-- |
1.7% |
17 |
LMC Software
Limited |
1,950 |
1,950 |
-- |
1.7% |
18 |
IDOX* |
238 |
1,938 |
(32) |
1.7% |
19 |
Volumatic
Holdings |
216 |
1,921 |
(1,354) |
1.7% |
20 |
Locate
Bio |
1,753 |
1,753 |
-- |
1.5% |
21 |
VoxPopMe |
1,660 |
1,660 |
13 |
1.4% |
22 |
Turbine
Simulated Cell Technologies |
1,433 |
1,621 |
188 |
1.4% |
23 |
Camena
Bioscience |
1,594 |
1,594 |
-- |
1.4% |
24 |
Social Value
Portal |
1,573 |
1,573 |
-- |
1.4% |
25 |
Enate |
1,516 |
1,516 |
-- |
1.4% |
26 |
Administrate |
2,374 |
1,495 |
(406) |
1.3% |
27 |
Risk
Ledger |
1,412 |
1,412 |
-- |
1.2% |
28 |
Moonshot |
1,329 |
1,329 |
-- |
1.2% |
29 |
Optellum |
1,276 |
1,276 |
-- |
1.1% |
30 |
Centuro
Global |
1,038 |
1,038 |
-- |
0.9% |
31 |
MIP
Discovery |
1,025 |
1,025 |
-- |
0.9% |
32 |
Seahawk
Bidco |
513 |
993 |
525 |
0.9% |
33 |
Send
Technology Solutions |
974 |
974 |
-- |
0.8% |
34 |
Wobble
Genomics |
968 |
968 |
-- |
0.8% |
35 |
Warwick
Acoustics |
964 |
964 |
-- |
0.8% |
36 |
Axis Spine
Technologies |
955 |
955 |
-- |
0.8% |
37 |
Wonderush Ltd
(t/a Hownow) |
947 |
947 |
-- |
0.8% |
38 |
iOpt |
941 |
941 |
-- |
0.8% |
39 |
Oddbox |
1,093 |
798 |
45 |
0.7% |
40 |
Naitive
Technologies |
787 |
787 |
-- |
0.7% |
41 |
Intuitive
Holding |
1,674 |
742 |
56 |
0.6% |
42 |
Northrow |
1,495 |
690 |
(108) |
0.6% |
43 |
Duke &
Dexter |
1,237 |
644 |
(602) |
0.6% |
44 |
Rego
Technologies (t/a Upp)(formerly Volo) |
2,369 |
568 |
98 |
0.5% |
45 |
Synthesized |
510 |
510 |
-- |
0.4% |
46 |
Fresh Approach
(UK) Holdings |
924 |
478 |
(380) |
0.4% |
47 |
Thanksbox (t/a
Mo) |
1,685 |
415 |
(229) |
0.4% |
48 |
Atlas
Cloud |
704 |
387 |
(317) |
0.3% |
49 |
RTC
Group* |
436 |
345 |
287 |
0.3% |
50 |
musicMagpie* |
238 |
302 |
(809) |
0.3% |
51 |
Sen
Corporation |
681 |
296 |
(384) |
0.3% |
52 |
Arnlea
Holdings |
1,305 |
238 |
11 |
0.2% |
53 |
Sorted |
182 |
182 |
(29) |
0.2% |
54 |
Customs
Connect Group |
1,525 |
112 |
(9) |
0.1% |
55 |
Angle* |
131 |
45 |
(28) |
0.0% |
56 |
Velocity
Composites* |
90 |
32 |
(1) |
0.0% |
57 |
Quotevine |
1,311 |
-- |
-- |
0.0% |
58 |
Nutshell |
734 |
-- |
(385) |
0.0% |
59 |
Ablatus
Therapeutics |
612 |
-- |
-- |
0.0% |
Total venture capital investments |
81,692 |
82,574 |
|
71.9% |
Net current assets |
|
32,257 |
|
28.1% |
Net assets |
|
114,831 |
|
100.0% |
*Quoted on AIM
**This change in ‘like for like’ valuations is a comparison of the
31 March 2024 valuations with the 31 March 2023 valuations (or
where a new investment has been made in the year, the investment
amount), having adjusted for any partial disposals, loan stock
repayments or new and follow-on investments in the year.
Risk management
The Board carries out a regular and robust assessment of the risk
environment in which the Company operates and seeks to identify new
risks as they emerge. The principal and emerging risks and
uncertainties identified by the Board which might affect the
Company’s business model and future performance, and the steps
taken with a view to their mitigation, are as follows:
Investment and liquidity risk: investment in
smaller and unquoted companies, such as those in which the Company
invests, involves a higher degree of risk than investment in larger
listed companies because they generally have limited product lines,
markets and financial resources and may be more dependent on key
individuals. The securities of smaller companies in which the
Company invests are typically unlisted, making them illiquid, and
this may cause difficulties in valuing and disposing of the
securities. The Company may invest in businesses whose shares are
quoted on AIM – the fact that a share is quoted on AIM does not
mean that it can be readily traded and the spread between the
buying and selling prices of such shares may be wide.
Mitigation: the Directors aim to limit the risk
attaching to the portfolio as a whole by careful selection, close
monitoring and timely realisation of investments, by carrying out
rigorous due diligence procedures and maintaining a wide spread of
holdings in terms of financing stage and industry sector within the
rules of the VCT scheme. The Board reviews the investment portfolio
with the Investment Adviser on a regular basis.
Financial risk: most of the Company’s
investments involve a medium to long-term commitment and many are
illiquid.
Mitigation: the Directors consider that it is
inappropriate to finance the Company’s activities through borrowing
except on an occasional short-term basis. Accordingly they seek to
maintain a proportion of the Company’s assets in cash or cash
equivalents in order to be in a position to pursue new unquoted
investment opportunities and to make follow-on investments in
existing portfolio companies. The Company has very little direct
exposure to foreign currency risk and does not enter into
derivative transactions.
Economic risk: events such as economic
recession or general fluctuation in stock markets, exchange rates
and interest rates may affect the valuation of investee companies
and their ability to access adequate financial resources, as well
as affecting the Company’s own share price and discount to net
asset value.
The level of economic risk has been elevated most recently by
inflationary pressures, interest rate increases, and supply
shortages.
Mitigation: the Company invests in a diversified
portfolio of investments spanning various industry sectors, and
maintains sufficient cash reserves to be able to provide additional
funding to investee companies where it is appropriate and in the
interests of the Company to do so. The Investment Adviser typically
provides an investment executive to actively support the board of
each unquoted investee company. At all times, and particularly
during periods of heightened economic uncertainty, the investment
executives share best practice from across the portfolio with
investee management teams in order to mitigate economic risk.
Stock market risk: some of the Company’s
investments are quoted on AIM and will be subject to market
fluctuations upwards and downwards. External factors such as
terrorist activity, political activity or global health crises, can
negatively impact stock markets worldwide. In times of adverse
sentiment there may be very little, if any, market demand for
shares in smaller companies quoted on AIM.
Mitigation: the Company’s AIM-quoted investments
are actively managed by Mercia, and the Board keeps the portfolio
and the actions taken under ongoing review.
Credit risk: the Company holds a number of
financial instruments and cash deposits and is dependent on the
counterparties discharging their commitment.
Mitigation: the Directors review the
creditworthiness of the counterparties to these instruments and
cash deposits and seek to ensure there is no undue concentration of
credit risk with any one party.
Legislative and regulatory risk: in order to
maintain its approval as a VCT, the Company is required to comply
with current VCT legislation in the UK. Changes to UK legislation
in the future could have an adverse effect on the Company’s ability
to achieve satisfactory investment returns whilst retaining its VCT
approval.
Mitigation: the Board and the Investment Adviser
monitor political developments and where appropriate seek to make
representations either directly or through relevant trade
bodies.
Internal control risk: the Company’s assets
could be at risk in the absence of an appropriate internal control
regime which is able to operate effectively even during times of
disruption.
Mitigation: the Board regularly reviews the system
of internal controls, both financial and non-financial, operated by
the Company and the Investment Adviser. These include controls
designed to ensure that the Company’s assets are safeguarded and
that proper accounting records are maintained.
VCT-qualifying status risk: while it is the
intention of the Directors that the Company will be managed so as
to continue to qualify as a VCT, there can be no guarantee that
this status will be maintained. A failure to continue meeting the
qualifying requirements could result in the loss of VCT tax relief,
the Company losing its exemption from corporation tax on capital
gains, to shareholders being liable to pay income tax on dividends
received from the Company and, in certain circumstances, to
shareholders being required to repay the initial income tax relief
on their investment.
Mitigation: the Investment Adviser keeps the
Company’s VCT-qualifying status under continual review and its
reports are reviewed by the Board on a quarterly basis. The Board
has also retained Philip Hare & Associates LLP to undertake an
independent VCT status monitoring role.
The Board continually assesses and monitors emerging risks that
could impact the Company’s operations and strategic objectives. As
part of the risk assessment process, the Board evaluates a wide
range of potential threats and uncertainties that may arise from
evolving market dynamics, regulatory changes, technological
advancements, geopolitical developments, and other external
factors. By remaining aware of emerging risks, the Board ensures
that the Company is better equipped to anticipate challenges and
adapt swiftly to changing circumstances.
Directors’ responsibilities
The Directors are responsible for preparing the annual report
and financial statements in accordance with applicable law and
regulations.
Company law requires the Directors to prepare financial
statements for each financial year. Under that law they are
required to prepare the financial statements in accordance with UK
accounting standards, including FRS 102 ‘The Financial Reporting
Standard applicable in the UK and Republic of Ireland’.
Under company law the Directors must not approve the financial
statements unless they are satisfied that they give a true and fair
view of the state of affairs of the Company and of its profit or
loss for the year. In preparing these financial statements, the
Directors are required to:
- select suitable accounting policies and then apply them
consistently;
- make judgements and estimates that are reasonable and
prudent;
- state whether applicable UK accounting standards have been
followed, subject to any material departures disclosed and
explained in the financial statements;
- assess the Company’s ability to continue as a going concern,
disclosing, as applicable, matters related to going concern; and
use the going concern basis of accounting unless they either intend
to liquidate the Company or to cease operations, or have no
realistic alternative but to do so.
The Directors are responsible for keeping adequate accounting
records that are sufficient to show and explain the Company’s
transactions and disclose with reasonable accuracy at any time the
financial position of the Company and enable them to ensure that
its financial statements comply with the Companies Act 2006. They
are responsible for such internal control as they determine is
necessary to enable the preparation of financial statements that
are free from material misstatement, whether due to fraud or error,
and have general responsibility for taking such steps as are
reasonably open to them to safeguard the assets of the Company and
to prevent and detect fraud and other irregularities.
Under applicable law and regulations, the Directors are also
responsible for preparing a Strategic Report, Directors’ Report,
Directors’ Remuneration Report and Corporate Governance Statement
that complies with that law and those regulations.
The Directors are responsible for the maintenance and integrity
of the corporate and financial information included on the
Company’s website. Legislation in the UK governing the preparation
and dissemination of financial statements may differ from
legislation in other jurisdictions.
The Directors confirm that to the best of their knowledge:
- the financial statements, prepared in accordance with the
applicable set of accounting standards, give a true and fair view
of the assets, liabilities, financial position and profit or loss
of the Company; and
- the Strategic Report and Directors’ Report includes a fair
review of the development and performance of the business and the
position of the issuer, together with a description of the
principal risks and uncertainties that they face.
The Directors consider the annual report and accounts, taken as
a whole, is fair, balanced and understandable and provides the
information necessary for shareholders to assess the Company’s
position and performance, business model and strategy.
The Directors of the company at the date of this
statement were Mr S J Constantine (Chair), Mr R J Green, Ms D N
Hudson, Mr D A Mayes, and Ms B A Sutcliffe.
Other matters
The above summary of results for the year ended
31 March 2024 does not constitute statutory financial statements
within the meaning of Section 435 of the Companies Act 2006 and has
not been delivered to the Registrar of Companies. Statutory
financial statements will be filed with the Registrar of Companies
in due course; the independent auditor’s report on those financial
statements under Section 495 of the Companies Act 2006 is
unqualified, does not include any reference to matters to which the
auditor drew attention by way of emphasis without qualifying the
report and does not contain a statement under Section 498 (2) or
(3) of the Companies Act 2006.
The calculation of the return per share is based
on the return after tax for the year of £3,216,000 (18 month period
ending 31 March 2023: minus £9,923,000) and on 179,260,563 (18
month period ending 31 March 2023: 165,209,895) shares, being the
weighted average number of shares in issue during the period.
The calculation of net asset value per share as
at 31 March 2024 is based on net assets of £114,831,000 (31 March
2023: £102,497,000) divided by the 190,460,878 (31 March 2023:
164,920,166) shares in issue at that date.
The proposed final dividend of 1.6 pence per
share for the year ended 31 March 2024 will, if approved by
shareholders at the Annual General Meeting, be paid on 23 August
2024 to shareholders on the register on 26 July 2024
The full annual report including financial
statements for the year ended 31 March 2024 is expected to be made
available to shareholders on or around 28 June 2024 and will be
available to the public at the registered office of the company at
Forward House, 17 High Street, Henley-in-Arden B95 5AA and on the
company’s website.
Neither the contents of the Mercia Asset
Management PLC website, nor the contents of any website accessible
from hyperlinks on the Mercia Asset Management PLC website (or any
other website), are incorporated into, or form part of, this
announcement.
Northern Venture (LSE:NVT)
Historical Stock Chart
Von Okt 2024 bis Nov 2024
Northern Venture (LSE:NVT)
Historical Stock Chart
Von Nov 2023 bis Nov 2024